BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48:7-17. [PMID: 31347138 DOI: 10.1007/s15010-019-01345-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang J, Liu Z, Liu L, Huang M, Huang Y. Th22/IL-22 mediates the progression of HBV-related hepatocellular carcinoma via STAT3. Cytotechnology. [DOI: 10.1007/s10616-021-00517-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yang J, Pan G, Guan L, Liu Z, Wu Y, Liu Z, Lu W, Li S, Xu H, Ouyang G. The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels. Cancer Med 2022. [PMID: 34989144 DOI: 10.1002/cam4.4530] [Reference Citation Analysis]
3 Rodriguez S, Skeet K, Mehmetoglu-Gurbuz T, Goldfarb M, Karri S, Rocha J, Shahinian M, Yazadi A, Poudel S, Subramani R. Phytochemicals as an Alternative or Integrative Option, in Conjunction with Conventional Treatments for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5753. [PMID: 34830907 DOI: 10.3390/cancers13225753] [Reference Citation Analysis]
4 Shen N, Wang P, Li Y, Zhu Y, Gong Y, Zhong R, Lu Y, Cheng L. Nonreceptor protein tyrosine phosphatases (NRPTPs) gene family associates with the risk of hepatocellular carcinoma in a Chinese hepatitis B virus-related subjects. Mol Carcinog 2020;59:980-8. [PMID: 32484301 DOI: 10.1002/mc.23228] [Reference Citation Analysis]
5 Saad AM, Abdel-Megied AES, Elbaz RA, Hassab El-Nabi SE, Elshazli RM. Genetic variants of APEX1 p.Asp148Glu and XRCC1 p.Gln399Arg with the susceptibility of hepatocellular carcinoma. J Med Virol 2021. [PMID: 34289138 DOI: 10.1002/jmv.27217] [Reference Citation Analysis]
6 Huang C, Luo H, Huang Y, Fang C, Zhao L, Li P, Zhong C, Liu F. AURKB, CHEK1 and NEK2 as the Potential Target Proteins of Scutellaria barbata on Hepatocellular Carcinoma: An Integrated Bioinformatics Analysis. Int J Gen Med 2021;14:3295-312. [PMID: 34285555 DOI: 10.2147/IJGM.S318077] [Reference Citation Analysis]
7 [DOI: 10.1101/568147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Li G, Deng L, Huang N, Cui Z, Wu Q, Ma J, Pan Q, Sun F. m6A mRNA Methylation Regulates LKB1 to Promote Autophagy of Hepatoblastoma Cells through Upregulated Phosphorylation of AMPK. Genes (Basel) 2021;12:1747. [PMID: 34828353 DOI: 10.3390/genes12111747] [Reference Citation Analysis]
9 Pu J, Wu X, Wu Y, Shao Z, Luo C, Tang Q, Wang J, Wei H, Lu Y. Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1. Aging (Albany NY) 2021;13:12207-23. [PMID: 33952719 DOI: 10.18632/aging.103797] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Liu L, Liu B, Yu J, Zhang D, Shi J, Liang P. Development of a Toll-Like Receptor-Based Gene Signature That Can Predict Prognosis, Tumor Microenvironment, and Chemotherapy Response for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:729789. [PMID: 34621787 DOI: 10.3389/fmolb.2021.729789] [Reference Citation Analysis]
11 Lin J, Zhang H, Yu H, Bi X, Zhang W, Yin J, Zhao P, Liang X, Qu C, Wang M, Hu M, Liu K, Wang Y, Zhou Z, Wang J, Tan X, Liu W, Shao Z, Cai J, Tang W, Cao G. Epidemiological Characteristics of Primary Liver Cancer in Mainland China From 2003 to 2020: A Representative Multicenter Study. Front Oncol 2022;12:906778. [DOI: 10.3389/fonc.2022.906778] [Reference Citation Analysis]
12 Magon KL, Parish JL. From infection to cancer: how DNA tumour viruses alter host cell central carbon and lipid metabolism. Open Biol 2021;11:210004. [PMID: 33653084 DOI: 10.1098/rsob.210004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Pan Y, Han G. Analysis of Clinical Characteristics of Hepatitis B and Alcohol-Related Liver Cancer. Comput Math Methods Med 2021;2021:9752534. [PMID: 34840599 DOI: 10.1155/2021/9752534] [Reference Citation Analysis]
14 Rao S, Hossain T, Mahmoudi T. 3D human liver organoids: An in vitro platform to investigate HBV infection, replication and liver tumorigenesis. Cancer Lett 2021;506:35-44. [PMID: 33675983 DOI: 10.1016/j.canlet.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Xu H, Cao D, Zheng Y, Zhou D, Chen X, Lei J, Ge W, Xu X. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol 2021;100:108135. [PMID: 34530205 DOI: 10.1016/j.intimp.2021.108135] [Reference Citation Analysis]
16 Chen SZ, Ling Y, Yu LX, Song YT, Chen XF, Cao QQ, Yu H, Chen C, Tang JJ, Fan ZC, Miao YS, Dong YP, Tao JY, Monga SPS, Wen W, Wang HY. 4-phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR-α. Clin Transl Med 2021;11:e379. [PMID: 33931972 DOI: 10.1002/ctm2.379] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Hu YM, Ran R, Yang C, Liu SM. The diagnostic and prognostic implications of PRKRA expression in HBV-related hepatocellular carcinoma. Infect Agent Cancer 2022;17:34. [PMID: 35729579 DOI: 10.1186/s13027-022-00430-6] [Reference Citation Analysis]
18 Xue H, Qin L, Zhang L, Li X, Wu F, Wang W, Wang C, Diao W, Jiang B, Lian B, Wu J, Bai J, Sun T, Zhao C, Qu M, Yu W, Wang Y, Gao Z. Preparation of docetaxel-loaded, glycyrrhetinic acid-modified nanoparticles and their liver-targeting and antitumor activity. Exp Ther Med 2021;22:1144. [PMID: 34471430 DOI: 10.3892/etm.2021.10578] [Reference Citation Analysis]
19 Tefera J, Revzin M, Chapiro J, Savic LJ, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma-a new variant of liver cancer: clinical, pathological and radiological correlation. J Clin Pathol. 2021;74:31-35. [PMID: 32430483 DOI: 10.1136/jclinpath-2020-206574] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
20 Lam BQ, Srivastava R, Morvant J, Shankar S, Srivastava RK. Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance. Cells 2021;10:3077. [PMID: 34831299 DOI: 10.3390/cells10113077] [Reference Citation Analysis]
21 Kong M, Gao Y, Guo X, Xie Y, Yu Y. Role of the CTRP family in tumor development and progression. Oncol Lett 2021;22:723. [PMID: 34429763 DOI: 10.3892/ol.2021.12984] [Reference Citation Analysis]
22 Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
23 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
24 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
25 Pu R, Liu W, Zhou X, Chen X, Hou X, Cai S, Chen L, Wu J, Yang F, Tan X, Yin J, Wang X, Cao G. The Effects and Underlying Mechanisms of Hepatitis B Virus X Gene Mutants on the Development of Hepatocellular Carcinoma. Front Oncol 2022;12:836517. [PMID: 35223517 DOI: 10.3389/fonc.2022.836517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kaźmierczak-Siedlecka K, Daca A, Roviello G, Catalano M, Połom K. Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis-what is currently known? Gastric Cancer 2021. [PMID: 34741681 DOI: 10.1007/s10120-021-01260-y] [Reference Citation Analysis]
27 Wang P, Li Y, Li L, Zhong R, Shen N. MBOAT7-TMC4 rs641738 Is Not Associated With the Risk of Hepatocellular Carcinoma or Persistent Hepatitis B Infection. Front Oncol 2021;11:639438. [PMID: 34113561 DOI: 10.3389/fonc.2021.639438] [Reference Citation Analysis]
28 Wang H, Xu F, Yang F, Lv L, Jiang Y. Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma. Sci Rep 2021;11:14611. [PMID: 34272452 DOI: 10.1038/s41598-021-93998-9] [Reference Citation Analysis]
29 Wu Y, Lin Z, Luo M, Yu X, Chen S, Liu L. Effects of genetic polymorphisms in INTS10 and their interaction with environmental factors on progression from persistent HBV infection to hepatocellular carcinoma. Mol Carcinog 2021;60:620-6. [PMID: 34133796 DOI: 10.1002/mc.23328] [Reference Citation Analysis]
30 Tsujita Y, Sofue K, Ueshima E, Ueno Y, Hori M, Murakami T. Clinical Application of Quantitative MR Imaging in Nonalcoholic Fatty Liver Disease. Magn Reson Med Sci 2022. [PMID: 35584952 DOI: 10.2463/mrms.rev.2021-0152] [Reference Citation Analysis]
31 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
32 Chen Z, Zou Y, Zhang Y, Chen Z, Wu F, Jin H, Shi N, Rai SN. A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-17. [DOI: 10.1155/2022/8109771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Meng F, Liu J, Lu T, Zang L, Wang J, He Q, Zhou A. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics 2021;21:264-77. [PMID: 34095464 DOI: 10.1016/j.omto.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Li X, Guo Y, Wang X, Ge A, Wang H, Fan K, Guo C. Clinical significance of serum miR-487b in HBV-related hepatocellular carcinoma and its potential mechanism. Infect Dis (Lond) 2021;53:546-54. [PMID: 33783293 DOI: 10.1080/23744235.2021.1901981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Pisaturo M, Di Fraia A, Occhiello L, Minichini C, Starace M, Iodice V, Farella N, Stanzione M, Coppola N. Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma. Infect Drug Resist 2021;14:5199-208. [PMID: 34908854 DOI: 10.2147/IDR.S337647] [Reference Citation Analysis]
36 Zhang K, Fang T, Shao Y, Wu Y. TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 Signaling Axis Promotes Viability, Migration, Invasion and EMT of Hepatocellular Carcinoma Cells. Cancer Manag Res 2021;13:7087-99. [PMID: 34531686 DOI: 10.2147/CMAR.S297765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang X, Chen Y, Dong K, Ma Y, Jin Q, Yin S, Zhu X, Wang S. Effects of FER1L4-miR-106a-5p/miR-372-5p-E2F1 regulatory axis on drug resistance in liver cancer chemotherapy. Mol Ther Nucleic Acids 2021;24:449-61. [PMID: 33868788 DOI: 10.1016/j.omtn.2021.02.006] [Reference Citation Analysis]
38 Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 2021;56:158-67. [PMID: 33219410 DOI: 10.1007/s00535-020-01748-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021;11:5464-90. [PMID: 33859758 DOI: 10.7150/thno.54822] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
40 Chemin I, Pujol FH. Special Issue: “Updates on HBV Infection”. Microorganisms 2022;10:580. [DOI: 10.3390/microorganisms10030580] [Reference Citation Analysis]
41 Wang Y, Wang W, Wang M, Shi J, Jia X, Dang S, Granito A. A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-15. [DOI: 10.1155/2022/5389044] [Reference Citation Analysis]
42 He C, Wei Q, Zhu J, Qin Q, Wang H, Liu S. Clinical value of assessing serum levels of inflammatory cytokines in the early diagnosis of patients with primary liver carcinoma: a retrospective observational study. Journal of Bio-X Research 2021;4:29-35. [DOI: 10.1097/jbr.0000000000000084] [Reference Citation Analysis]
43 Nassar ES, Elkalbashawy YA, Kamal A, Zakaria NHE. Galectin-3 is not useful for hepatocellular carcinoma surveillance in cirrhotic patients but it may be a marker of cirrhosis development. Clin Exp Hepatol 2021;7:74-8. [PMID: 34027118 DOI: 10.5114/ceh.2021.104385] [Reference Citation Analysis]
44 Attal N, Sullivan MT, Girardi CA, Thompson KJ, McKillop IH. Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression. Transl Oncol 2021;14:100975. [PMID: 33290990 DOI: 10.1016/j.tranon.2020.100975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Pan J, Chao NX, Zhang YY, Huang TM, Chen CX, Qin QH, Guo JH, Huang RS, Luo GR. Upregulating KTN1 promotes Hepatocellular Carcinoma progression. J Cancer 2021;12:4791-809. [PMID: 34234850 DOI: 10.7150/jca.55570] [Reference Citation Analysis]
46 Melnik BC. Dairy consumption and hepatocellular carcinoma risk. Ann Transl Med 2021;9:736. [PMID: 33987434 DOI: 10.21037/atm-2020-ubih-06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tang C, Hu C, Zhou Y, Song Y, Li M, Liao M, Sun J, Zhong C, Zhou L, Lin Z, Zhou Y. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study]. Nan Fang Yi Ke Da Xue Xue Bao 2021;41:313-8. [PMID: 33849820 DOI: 10.12122/j.issn.1673-4254.2021.03.01] [Reference Citation Analysis]
48 Onan E, Akkiz H, Sandikci MU, Üsküdar O, Öztürk AB. Importance of circulating microRNA-122 for hepatocellular carcinoma. Cukurova Medical Journal 2021;46:1300-8. [DOI: 10.17826/cumj.934776] [Reference Citation Analysis]
49 Yang H, Deng Q, Ni T, Liu Y, Lu L, Dai H, Wang H, Yang W. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. Int J Biol Sci 2021;17:4207-22. [PMID: 34803493 DOI: 10.7150/ijbs.64714] [Reference Citation Analysis]
50 Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer Rep (Hoboken) 2022;:e1613. [PMID: 35302279 DOI: 10.1002/cnr2.1613] [Reference Citation Analysis]
51 Wang J, Du L, Tang H. Suppression of Interferon-α Treatment Response by Host Negative Factors in Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:784172. [PMID: 34901094 DOI: 10.3389/fmed.2021.784172] [Reference Citation Analysis]
52 Zhan Q, Xu JH, Yu YY, Lo KK E, Felicianna, El-Nezami H, Zeng Z. Human immune repertoire in hepatitis B virus infection. World J Gastroenterol 2021; 27(25): 3790-3801 [PMID: 34321844 DOI: 10.3748/wjg.v27.i25.3790] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Yin X, Yu H, He XK, Yan SX. Prognostic and biological role of the N-Myc downstream-regulated gene family in hepatocellular carcinoma. World J Clin Cases 2022; 10(7): 2072-2086 [DOI: 10.12998/wjcc.v10.i7.2072] [Reference Citation Analysis]
54 Xu Y, Mu W, Li J, Ba Q, Wang H. Chronic cadmium exposure at environmental-relevant level accelerates the development of hepatotoxicity to hepatocarcinogenesis. Sci Total Environ 2021;783:146958. [PMID: 33866181 DOI: 10.1016/j.scitotenv.2021.146958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites 2021;11:273. [PMID: 33925362 DOI: 10.3390/metabo11050273] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Liang H, Xu M, Xiong Z, Hu K, Yang J, Cao M, Zhong Z, Yao Z, Deng M, Liu B. Identification of miRNAs as diagnostic and prognostic markers in hepatocellular carcinoma. Aging (Albany NY) 2021;13:6115-33. [PMID: 33617479 DOI: 10.18632/aging.202606] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
57 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]
58 De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid MM, Rao S, Bazrafshan A, Verstegen MM, Pourfarzad F, Koutsothanassis C, Gehart H, Kan TW, Palstra RJ, Boucher C, IJzermans JN, Huch M, Boj SF, Vries R, Clevers H, van der Laan LJ, Hatzis P, Mahmoudi T. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife 2021;10:e60747. [PMID: 34328417 DOI: 10.7554/eLife.60747] [Reference Citation Analysis]
59 Li M, Liu Z, Wang J, Liu H, Gong H, Li S, Jia M, Mao Q. Systematic Analysis Identifies a Specific RNA-Binding Protein-Related Gene Model for Prognostication and Risk-Adjustment in HBV-Related Hepatocellular Carcinoma. Front Genet 2021;12:707305. [PMID: 34422009 DOI: 10.3389/fgene.2021.707305] [Reference Citation Analysis]
60 Zhong X, Luo M, Wu Y, Zhou X, Yu X, Liu L, Chen S. Genetic variants in STAT4 and their interactions with environmental factors for the incidence of hepatocellular carcinoma. Cancer Biomark 2021;32:3-9. [PMID: 33896832 DOI: 10.3233/CBM-203162] [Reference Citation Analysis]
61 Velmurugan BK, Hsieh M, Lin C, Ho H, Hsieh M. Dehydrocrenatidine Induces Liver Cancer Cell Apoptosis by Suppressing JNK-Mediated Signaling. Pharmaceuticals 2022;15:402. [DOI: 10.3390/ph15040402] [Reference Citation Analysis]
62 Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, Yan P, Liang X, Yu T, Wang Y, Cai X. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:11466-84. [PMID: 32579541 DOI: 10.18632/aging.103231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Xie Y, Tian H, Xiang B, Zhang Y, Liu J, Cai Z, Xiang H. Transarterial chemoembolization plus sorafenib versus sorafenib for intermediate-advanced hepatocellular carcinoma: A meta-analysis comparing clinical outcomes. Medicine (Baltimore) 2021;100:e26958. [PMID: 34414963 DOI: 10.1097/MD.0000000000026958] [Reference Citation Analysis]
64 Petriv N, Neubert L, Vatashchuk M, Timrott K, Suo H, Hochnadel I, Huber R, Petzold C, Hrushchenko A, Yatsenko AS, Shcherbata HR, Wedemeyer H, Lichtinghagen R, Falfushynska H, Lushchak V, Manns MP, Bantel H, Semchyshyn H, Yevsa T. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer. Oncoimmunology 2021;10:1874159. [PMID: 33628620 DOI: 10.1080/2162402X.2021.1874159] [Reference Citation Analysis]